BTK blockers make headway in multiple sclerosis
Elie Dolgin • January 11, 2021
By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.
Continue reading at Nature Biotechnology.
How a tissue-swelling method brought super-resolution imaging to the masses.
In response to cellular stress, proteins become ensnared in chemical traffic jams, creating a kind of widespread sluggishness scientists call “proteolethargy.”